Merck slims diabetes lineup

Share this article:
Merck slims diabetes lineup
Merck slims diabetes lineup

Merck is cutting Juvisync from its diabetes lineup. Philly.com reports that the drug maker is ending distribution of its diabetes-cholesterol mix of sitgaliptin/simvastain tablet in the US and Puerto Rico.

The company's R&D chief Roger Perlmutter has said he is dedicated to keeping the company focused on drugs that work and drugs that sell. “This did not sell,” notes Philly.com.

Launched in 2011, the product was designed to offer something different in the metabolics space: the only pill packing a DPP-IV inhibitor (Januvia) and, for diabetics who need its lipid-lowering ability, a statin (Zocor).

At the time, neither DPP-IV Onglyza, from Bristol-Myers Squibb/AstraZeneca, nor rival Tradjenta, from Boehringer Ingelheim/Eli Lilly, had such a pairing in their lineups, and neither does today.

Since then, Takeda launched a DPP-IV, Nesina, and two combination pills. Oseni integrates the active ingredient in Nesina with pioglitazone, making it the first DPP-IV + TZD combo pill. The other, Kazano, combined Nesina with metformin, the widely used anti-diabetes medication.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.